604 related articles for article (PubMed ID: 26372962)
1. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
6. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
[TBL] [Abstract][Full Text] [Related]
7. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
Wu X; Wang Y; Wan S; Zhang J
J Biomol Struct Dyn; 2018 Sep; 36(12):3106-3113. PubMed ID: 28893136
[TBL] [Abstract][Full Text] [Related]
8. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
Ye M; Zhang X; Li N; Zhang Y; Jing P; Chang N; Wu J; Ren X; Zhang J
Oncotarget; 2016 Mar; 7(11):12289-304. PubMed ID: 26802023
[TBL] [Abstract][Full Text] [Related]
9. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
11. Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK.
Tian Y; Yu Y; Shen Y; Wan H; Chang S; Zhang T; Wan S; Zhang J
J Chem Inf Model; 2017 Apr; 57(4):977-987. PubMed ID: 28318251
[TBL] [Abstract][Full Text] [Related]
12. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.
Ou SH; Bartlett CH; Mino-Kenudson M; Cui J; Iafrate AJ
Oncologist; 2012; 17(11):1351-75. PubMed ID: 22989574
[TBL] [Abstract][Full Text] [Related]
15. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
[TBL] [Abstract][Full Text] [Related]
16. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway.
Ou SH; Tan J; Yen Y; Soo RA
Expert Rev Anticancer Ther; 2012 Apr; 12(4):447-56. PubMed ID: 22500682
[TBL] [Abstract][Full Text] [Related]
17. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.
Davare MA; Saborowski A; Eide CA; Tognon C; Smith RL; Elferich J; Agarwal A; Tyner JW; Shinde UP; Lowe SW; Druker BJ
Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19519-24. PubMed ID: 24218589
[TBL] [Abstract][Full Text] [Related]
18. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
Dziadziuszko R; Le AT; Wrona A; Jassem J; Camidge DR; Varella-Garcia M; Aisner DL; Doebele RC
J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
[TBL] [Abstract][Full Text] [Related]
19. First macrocyclic 3
Basit S; Ashraf Z; Lee K; Latif M
Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
[TBL] [Abstract][Full Text] [Related]
20. SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.
Xia ZJ; Ji YC; Sun DQ; Peng X; Gao YL; Fang YF; Zhao XD; Wang WB; Ding J; Geng MY; Ai J
Acta Pharmacol Sin; 2021 Jun; 42(6):998-1004. PubMed ID: 32918045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]